Sativa Wellness Group’s PhytoVista Laboratories achieves ISO17025 accreditation

Sativa Wellness Group plc (AQSE:SWEL) has announced that the Company’s subsidiary PhytoVista Laboratories has been granted accreditation to ISO/IEC 17025:2017, General requirements for the competence of testing and calibration laboratories.

Accreditation for the testing of cannabinoids has been granted by United Kingdom Accreditation Service (UKAS), the UK governments appointed National Accreditation Body.  The accreditation process determines the technical competence and integrity of organisations such as those offering testing services.

ISO17025 accreditation offers the Company a competitive advantage in regulated markets where organisations are required to test with an accredited laboratory.  This development also positions the Company well to take advantage of a growing international market and developing regulatory landscape.  The Company plans to increase the scope of testing covered by accreditation and penetrate other areas of testing, whilst continuing to develop and expand cannabinoid testing capabilities.

The Company is in the process of extending the Phytovista testing services to its laboratory in Poland to service Europe, and as part of that process it intends to implement the ISO17025 standard there.

Geremy Thomas Executive Chairman says: “This success supports the direction of the Sativa Wellness Group to be the gold standard in the testing industry, driving growth through providing trusted services”.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn

More articles like this

Sativa Wellness Group Management Share Compensation Arrangements

Sativa Wellness Group plc (AQSE:SWEL / CNSX:SWEL) today announced certain management share compensation arrangements and amendments that have been approved by the Board of Directors with a view to both incentivising and aligning management and shareholder interests. Firstly, following

Use of Cannabidiol for the treatment of Anxiety

A macro-analysis of 49 different research papers (focusing primarily on animal studies) on the effects of CBD regarding multiple anxiety or stress-oriented disorders, such as Post-Traumatic Stress Disorder, Generalised Anxiety Disorder, and Social Anxiety Disorder to

The “Runner’s High” and Endocannabinoids

A runner’s high is a sense of well-being some people experience after prolonged exercise. For decades, it was hypothesized that exercise-induced endorphin release is solely responsible for a runner’s high, but recent evidence has suggested that

CBD bioavailability and why it matters

Wealth, friends, and even spouses, if lost, can be regained or acquired again somehow. But the body, once gone, will never come back- no matter how hard we try to revive the life that’s lost. Our

Finding relief from aches and pains

Everyone at some point of their life will experience some aches and pain, and it could be because of a whole range of different reasons. For some of us, that would be a bit of joint

CBD and mental health: A systematic analysis

There is a lot of research about the positive effects of CBD and Mental Health.  This report is a systematic analysis of a multitude of different research papers and conducted trials with regards to CBD’s impact

General benefits of CBD

CBD has been reported to help people in a number of ways. From pain relief, memory, and sleep to name a few, there’s a chance that we could all benefit from CBD in one way or

CBD and Diabetes: How can it help?

Close to 4.9 million people in the UK have been diagnosed with diabetes, with a further 850,000 people suspected to be living with undiagnosed type 2 diabetes. To add on to this, 13.6 million people in

The effects of cannabidiol on cerebral blood flow

The primary aim of this research paper was to investigate how CBD influences cerebral blood flow (CBF) in regions involved in memory processing. It was conducted under a randomised, crossover, double-blind design in which 15 healthy

Sativa Wellness Group Report record Q3 revenues (Interview)

Sativa Wellness Group Inc. (AQSE:SWEL / CNSX:SWEL) CEO Mark Howells joins DirectorsTalk Interviews to discuss a record quarterly profit in Q3 2021. Mark talks us through the numbers, explains how sustainable the performance is and plans